- 1 Title: Clonal haematopoiesis is associated with major adverse cardiovascular events in
- 2 patients with hypertrophic cardiomyopathy.
- 3 Brief Title: Clonal haematopoiesis affects outcomes in HCM patients.
- 4 Fernando L. Scolari MD PhD^{a,b,c}, Darshan Brahmbhatt MBBChir MD(Res)^{a,b,d}, Sagi Abelson PhD^{e,f}
- 5 Deacon Lee MB ChB^a, Raymond H Kim MD PhD^{b,e,h,j}, Ali Pedarzadeh MD^a, Ali Sakhnini MD^a,
- 6 Arnon Adler MD MSc^a, Raymond H Chan MD MPH^{a,g}, John Dick PhD^{f,h}, Harry Rakowski MD^a and
- 7 Filio Billia MD PhD^{a,b,c*}

8 Affiliations:

- 9 a. Peter Munk Cardiac Centre, University Health Network, Toronto, ON, Canada
- 10 b. Ted Rogers Centre for Heart Research, Toronto, ON, Canada
- 11 c. Toronto General Hospital Research Institute, Toronto, ON, Canada
- 12 d. Mount Sinai Hospital, Toronto, ON, Canada
- e. Ontario Institute for Cancer Research, Toronto, ON, Canada
- 14 f. Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada
- 15 g. Institute for Clinical Evaluation Sciences, Toronto ON, Canada
- 16 h. Princess Margaret Cancer Centre, Toronto, ON, Canada
- j. Division of Clinical and Metabolic Genetics, Hospital for Sick Children, Toronto, ON, Canada

19 * Corresponding Author:

- 20 Dr. Filio Billia MD PhD
- 21 585 University Ave., 6EN-242
- 22 Toronto Ontario M5G 2N2
- 23 416-340-4800 x 6805
- 24 416-340-4012 (fax)
- 25 Email: Phyllis.billia@uhn.ca
- 26
- 27 <u>Twitter</u>: @FilioBillia @Scolari_Fernand @Doctor_Darshan
- 28 <u>Tweet:</u> Clonal haematopoiesis confers a higher risk of adverse outcomes in patients with
- 29 hypertrophic cardiomyopathy and sarcomeric gene mutation, including higher degree of
- 30 fibrosis and major adverse cardiovascular events.
- 31 Hashtags: #HCM; #CHinHCM; #
- 32 Word count (not including title, abstract, acknowledgment, references, tables, and figure
- 33 legends): 2977
- 34 Funding: This work was supported by the Peter Munk Cardiac Centre Innovation Fund.
- 35 Disclosures: FB receives grant funding from Abbott Laboratories, Canadian Institutes for Health
- Research. AA is a Consultant for Bristol-Myers-Squibb.
- 37

38 KEY POINTS

- **Question:** Does clonal haematopoiesis (CH) affect the phenotype and outcomes among
- 40 hypertrophic cardiomyopathy (HCM) patients?
- 41 Findings: Among 799 patients, CH was found in 183 (22.9%) HCM patients. CH was associated
- 42 with symptoms, a higher burden of fibrosis and major cardiovascular events. Several cytokines
- 43 and troponin I were upregulated in gene-positive HCM patients with CH.
- **Meaning:** CH helps to identify those HCM patients at risk for serious adverse events and unveils
- 45 a potential inflammatory response mechanism that affects prognosis.

- 4/

56 ABSTRACT

Background & Aims: The heterogeneous phenotype of hypertrophic cardiomyopathy (HCM) is
still not fully understood. Clonal haematopoiesis (CH) is emerging as a cardiovascular risk factor
potentially associated with adverse clinical events. The prevalence, phenotype and outcomes
related to CH in HCM patients was evaluated.

Methods:_Patients with HCM and available biospecimens from the Peter Munk Cardiac Centre Cardiovascular Biobank were subjected to targeted sequencing for 35 myeloid genes associated with CH. CH prevalence, clinical characteristics, morphological phenotypes assessed by echocardiogram and cardiac magnetic resonance and outcomes were assessed. All patients were evaluated for a 71-plex cytokines/chemokines, troponin I and B-type natriuretic peptide analysis. Major cardiovascular events (MACE) were defined as appropriate ICD shock, stroke, cardiac arrest, orthotopic heart transplant and death.

Results: Among the 799 patients, CH was found in 183 (22.9%) HCM patients with sarcomeric germline mutations. HCM patients with CH were more symptomatic and with a higher burden of fibrosis than those without CH. CH was associated with MACE in those HCM patients with sarcomeric germline mutations [adjusted HR of 3.46 (95% CI 1.25-9.52; p=0.016)], with the highest risk among those that had *DNMT3A, TET2* and *ASXL1* mutations [adjusted HR of 7.23 (95% CI 1.79-29.13) p=0.005]. Several cytokines (IL-1ra, IL-6, IL-17F, TGFa, CCL21, CCL1, CCL8, and CCL17), and troponin I were upregulated in gene-positive HCM patients with CH.

- 75 **Conclusions:** These results indicate that CH in patients with HCM is associated with worse
- clinical outcomes. In the absence of CH, gene-positive patients with HCM have lower rates of
- 77 MACE.

78 Introduction

Hypertrophic cardiomyopathy (HCM) is an inherited cardiovascular disorder, affecting 1 in 500 79 80 individuals.¹ However, germline pathogenic or likely pathogenic (P/LP) genetic variants, such as 81 *MYH7* and *MYBPC3* genes, are identified in only 25-40% of patients.^{2,3} A wide heterogeneity and distinct morphologies of left ventricular (LV) hypertrophy are described, even amongst 82 family members carrying similar genetic variants.^{1,2,4–7} Interestingly, interstitial fibrosis is 83 detected in 40-70% of patients and is associated with sudden cardiac death (SCD). Although 84 HCM can be well tolerated, a subset of patients may require advanced treatments such as 85 orthotopic heart transplant (OHT) and LV assist devices.^{3,8} 86 The underlying mechanisms involved in the heterogeneous clinical presentation of HCM 87 patients are not well understood.^{3,8} Clonal haematopoiesis (CH) has emerged as a new risk 88 factor for the development of atherosclerosis, heart failure and cardiogenic shock and is 89 associated with worse outcomes.^{9–13} With aging, haematopoietic stem cells acquire somatic 90 mutations in genes regulating epigenetic DNA modifications and other pathways resulting in 91 clonal expansion. Experiments have shown that CH mutation may promote LV remodelling and 92 fibrosis through increased inflammation.^{14–17} Interestingly, a proteomic study has also shown 93 activation of inflammatory pathways in HCM.^{18,19} The role of CH driving inflammatory processes 94 that may lead to adverse clinical events in individuals with HCM is unknown. Therefore, we 95 sought to evaluate the prevalence of CH in a large HCM cohort and define its association with 96 97 phenotype and outcomes.

98 METHODS

99 Patient selection

100 This is a retrospective study to evaluate the association of CH in a cohort of patients with HCM. 101 We screened 4,400 patients from the HCM clinic of the Toronto General Hospital (Ontario, 102 Canada) from January 2001 to January 2022. We included 799 patients who were \geq 18 years of age, with a clinical diagnosis of HCM by current guidelines^{2,19}, cardiac magnetic resonance 103 104 imaging (MRI) and available biospecimens from the Peter Munk Cardiac Centre Cardiovascular 105 Biobank. All patients were systematically approached for biobanking. We excluded patients 106 with incomplete records, those that withdraw consent, or low biospecimen quality. This study 107 was approved by the UHN Research Ethics Board (#21-5313) and complied with the Declaration 108 of Helsinki.

109

110 **Definitions**

HCM was defined as the presence of maximal LV wall thickness (MLVWT) ≥15 mm, ≥13 mm in 111 the presence of a P/LP genetic variant or a family history of HCM, in the absence of other 112 113 causes. The assessment of P/LP variants was conducted using a previously published strategy by our group²⁰. All patients with HCM underwent cardiac MRI with late gadolinium enhancement 114 (LGE) for fibrosis quantification. The LGE was assessed visually and quantified manually as 115 previously validated.⁷ LGE extent was defined as the LGE mass percentage of the total LV mass. 116 117 We were able to quantify LGE in (84.1%) of patients. In the remaining 127 (15.9%) patients, we only included the qualitative measure of LGE. 118

119 Data collection, outcomes and follow-up

Clinical data were collected from a digital de-identified database. All collected data, including 120 121 echocardiogram and cardiac MRI, were the closest to the time of biospecimen collection. The 122 following outcomes were collected: appropriate implantable cardioverter defibrillator shock, stroke, cardiac arrest, OHT and death.²¹ We also condensed these as major cardiovascular 123 events (MACE) defined as the first occurrence of any. Only outcomes occurring after sample 124 125 collection were included. Patients were followed from the time of biospecimen collection to the 126 last visit to our institution. Loss to follow-up was defined as no interaction with the patient at 127 our institution in the preceding one year from chart assessment.

128

129 **Clonal haematopoiesis and cytokine assessment**

All peripheral blood biospecimens were collected during routine visits to the HCM clinic with 130 131 consent. For all patients, the biospecimen closest to the cardiac MRI assessment was selected. Briefly, the cytokine analysis was performed using a human cytokine/chemokine 71-plex assay 132 with the Luminex[™] 200 system by Eve Technologies Corp. (Alberta, Canada). In addition, the 133 134 levels of B-type natriuretic peptide and cardiac troponin I were evaluated. For CH genetic 135 analysis, a single molecule molecular inversion probe method targeting 35 myeloid genes related to CH was implemented as previously described^{9,22}. To call mutations we used SmMIP-136 tools²⁶. CH was considered in those patients with variants with a VAF \geq 2%. Additional details 137 138 are provided in the Supplementary materials.

140 Statistical analysis

141 The complete statistical methods are shown in the Supplementary materials. Continuous data 142 were evaluated for normality with Shapiro-Wilk test and histogram analysis and presented as 143 mean ± standard deviation or median (interquartile range). Categorical variables were presented as total count (frequency). A Student's T test or Mann-Whitney test was used to 144 compare continuous variables according to normal distribution. ANOVA and Chi-square test (or 145 Fisher's exact test) were used for comparing groups. Survival analysis was conducted using the 146 147 Kaplan-Meier method and differences assessed with the log-rank test. Cox proportional hazards 148 regressions were employed to compare survival rates, adjusting for age as a covariate. A 149 propensity score matching was used to address possible confounders according to CH. As a 150 sensitivity analysis, we also tested those with CH only in the three most common CH genes 151 (DNMT3A, TET2 and ASXL1). We used a statistical significance of 0.05 for all analyses and a two-152 sided p-value. All analyses were performed using SPSS, version 25.0 (SPSS Inc., NY, USA).

153 Results

154

155 summarized in Table 1. Briefly, the mean age of our cohort was 55.7±14.6 years, 547 patients 156 (68.5%) were males, with an age at the time of HCM diagnosis of 47.8±15.8 years. Germline genetic testing was performed on 712 (89.1%) patients, with a P/LP variant identified in 206 157 (25.8%) patients. P/LP variants were primarily in MYBPC3 (127, 61.6%) and MYH7 (53, 25.7%). 158 Mean MLVWT was 17.1±4.2 mm, whereas 170 (21.3%) patients exhibited a LV outflow tract 159 160 maximal gradient \geq 50 mmHg. The median time from biospecimen collection to the 161 echocardiogram was 0 (0-16) days and median time from biospecimen to MRI assessment was 162 2.2 (0.2-5.6) years.

We included 799 patients in the study and the overall characteristics of the cohort are

163

164 Clonal haematopoiesis prevalence and characteristics

165 All patients had an assessment of CH and all samples passed quality control specifications. CH mutations were observed in 183 (22.9%) patients with a median variant allele (VAF) frequency 166 of 6.7% (2.8-40.8). Of these patients, 136 (17.0%) had somatic mutations in the three most 167 168 common CH genes: DNMT3A in 70 (8.8%), TET2 in 51 (6.3%), and ASXL1 in 24 (3.0%), comprising 169 73.8% of all CH mutations (Figure 1A). The CH-associated gene mutations summary is shown in 170 Supplementary Table 1. Most patients (158, 19.8%) harboured a single mutation and of the 183 171 patients with CH (Figure 1B), 135 (73.7%) were >50 years old (Figure 1C). In relation to the HCM 172 diagnosis age, the majority, 94 (51.3%), were diagnosed after 50 years old.

Overall, clinical characteristics of CH patients were similar to those without CH (Table 1). There 173 174 was no statistical difference regarding age, age at HCM diagnosis, and comorbidities according 175 to CH status. Both groups underwent genetic testing equally. Family history of SCD was more 176 common among CH patients [11 (6%) vs. 26 (4.2%), p=0.048]. CH patients were more likely to 177 have a pacemaker implantation, [7 (3.8%) vs. 6 (1.0%), p=0.007] and to be treated with non-178 dihydropyridine calcium channel blockers [39 (21.3%) vs. 77 (12.5%), p=0.003]. 179 No differences were found in echocardiographic or cardiac MRI parameters, or other HCM 180 features such as syncope or abnormal blood pressure response (ABPR) at exercise according to 181 CH (Supplementary Table 2). However, the presence of an apical aneurysm [33 (5.4%) vs. 14 182 (7.7%), p=0.004] and death or need for OHT were higher among HCM patients with CH [6 (3.3%) 183 vs. 4 (0.6%), p=0.005]. MACE was also more frequent among patients with CH [12 (2.0%) vs. 9 184 (5.2%), p=0.026], with an unadjusted HR of 2.72 (95% CI 1.14-6.49; p=0.023), and adjusted HR

of 3.46 (95% CI 1.25-9.52; p=0.016). CH patients showed a worse survival in comparison to

those without CH as shown in the Kaplan-Meier curve (Log-Rank P=0.018) (Figure 2A).

187

188 Clonal haematopoiesis related to DNMT3A, TET2 and ASXL1

Since *DNMT3A*, *TET2* and *ASXL1* are the most frequent and more lethal CH-associated gene
mutations⁹, we performed a sub-analysis including these 3 genes and comparing to patients
without CH in other genes. Patients harbouring *DNMT3A*, *TET2* and *ASXL1* mutations were older
than their counterparts [58.1±14.5 vs. 55.3±14.6, p=0.046] and more likely to have a family
history of SCD [9 (6.7%) vs 26 (4.2%), p=0.035]. As we note in the broader CH analysis, these

194	patients were more likely to have hypertension, a P/LP HCM germline variant, a pacemaker and
195	treated with a non-dihydropyridine calcium channel blocker (Supplementary Table 3).
196	While patients with DNMT3A, TET2 and ASXL1 CH mutations exhibited a similar HCM
197	phenotype to those without CH (Supplementary Table 4), patients with CH showed a higher
198	mortality or need for OHT [6 (4.4%) vs. 4 (0.6%), p<0.0001] and MACE [8 (6.2%) vs. 12 (2.0%),
199	p=0.008]. The unadjusted HR for MACE was 3.25 (95% CI 1.32-7.98; p=0.010) and adjusted HR
200	3.34 (95% CI 1.33-8.42; p=0.010). Figure 2B shows the Kaplan-Meir curve with worse survival
201	for patients with CH (Log-Rank p=0.006).
202	
203	Clonal haematopoiesis in HCM patients with germline sarcomeric gene P/LP variant
204	HCM patients harbouring a germline sarcomeric P/LP variant are associated with early age at
205	diagnosis, higher MLVWT and worse outcomes. ²³ In our cohort, patients with a germline
206	sarcomeric P/LP variant were associated with worse MACE (HR 3.1, 95% CI 1.17-8.49, p=0.022).
207	As this subtype of HCM patients have a distinct clinical profile and are less likely to be
208	phenocopies, we sought to investigate the CH effect in this subset of patients. Only patients
209	with genetic screening were included [N=680 (85.1%)]. Clinical characteristics and outcomes are
209 210	with genetic screening were included [N=680 (85.1%)]. Clinical characteristics and outcomes are summarized in Supplementary Table 5 and in Table 2 respectively. Those with CH mutations
209 210 211	with genetic screening were included [N=680 (85.1%)]. Clinical characteristics and outcomes are summarized in Supplementary Table 5 and in Table 2 respectively. Those with CH mutations showed a trend towards a higher burden of symptoms (NYHA class II to IV) [15 (40.5%) vs. 47
209 210 211 212	with genetic screening were included [N=680 (85.1%)]. Clinical characteristics and outcomes are summarized in Supplementary Table 5 and in Table 2 respectively. Those with CH mutations showed a trend towards a higher burden of symptoms (NYHA class II to IV) [15 (40.5%) vs. 47 (28.0%), p=0.132]. CH was also associated with a higher burden of fibrosis as reflected by LGE in

214 1.00-5.38, p=0.048). A trend towards a higher degree of fibrosis in those patients with CH was

also observed [15.6 % (10.4-24.6) vs. 12.2 % (7.7-17.6), p=0.068]. CH patients did show a higher
frequency of ABPR at exercise [10 (62.5%) vs. 25 (29.8%), p=0.012]. Finally, CH was associated
with greater mortality or need for OHT [3 (8.1%) vs. 2 (1.2%), (p=0.013)] and MACE [5 (13.5%)
vs. 5 (3.0%), p=0.008], with an unadjusted HR of 5.28 (95% CI 1.51-18.4, p=0.009), and adjusted
HR of 6.89 (95% CI 1.78-26.6, p=0.005). Figure 2C shows the Kaplan-Meier survival curve
showing a worse survival for those with CH (log-rank p=0.003).

221 We then evaluated the HCM phenotype and clinical outcomes in those with germline

sarcomeric genes P/LP variants according to DNMT3A, TET2, and ASXL1 CH mutations. Baseline

223 characteristics were similar between groups (Supplementary Table 6). The amount of fibrosis

assessed by LGE was higher in those with CH [21.2% (13.7-41.8) vs. 12.2% (7.7-17.6), p=0.017].

225 CH patients showed a higher frequency of ABPR with exercise than those without CH [8 (66.7%)

vs. 25 (29.8%), p=0.012). Mortality or OHT was more common in the CH group than in those

without CH [3 (13.0%) vs. 2 (1.2%), p<0.0001], as well as MACE [4 (17.4%) vs. 5 (3.0%), p=0.003].

228 MACE was associated with CH with an unadjusted HR of 5.28 [(95%CI 1.51-18.41) p=0.009] and

for the specific DNMT3A, TET2 and ASXL1 CH-mutated genes had a HR of 5.76 [(95%CI 1.51-

230 21.94), p=0.010]. Figure 2C and 2D shows the Kaplan-Meier survival curve showing a worse

survival for those with CH and by specific CH mutations, respectively (log-rank p=0.007).

232

233 Propensity score matched analysis

234 A propensity score matching was performed to address potential confounding factors. The

group balance is shown in the Supplementary material. After the matching procedure, 514

patients without CH and 183 with CH were selected. Clinical characteristics, the HCM 236 237 phenotype and outcomes are shown in Supplementary tables 7 and 8, respectively. CH was associated with MACE with an unadjusted HR of 2.78 (95% CI 1.15-6.72; p=0.023) and an 238 239 adjusted HR of 2.47 (95% Cl 1.01-6.02; p=0.046). We then performed a subgroup analysis 240 according to CH and genotype. Patients with CH and germline P/LP variants were associated with higher MACE with an unadjusted HR of 11.3 (95% CI 3.28-39.4; p<0.0001) and an adjusted 241 HR of 12.0 (95% CI 3.4-41.8; p<0.0001). Similar results were observed testing for specific CH 242 243 mutations (DNMT3A, TET2 and ASXL1) with a HR of 6.06 (95%CI 1.47-24.94; p=0.013) and with 244 an adjusted HR of 7.31 (94% CI 1.66-32.09; p=0.008). The central figure shows the Kaplan-Meier survival curve and the forest plot for HR according to these subgroups. 245

246

247 **Biomarkers and cytokines/chemokines**

248 A panel of 71 cytokines and chemokines, B-type natriuretic peptide and cardiac troponin I were 249 evaluated in patients with a germline sarcomeric P/LP variant and levels were compared among 250 those with (N=37) or without CH (N=169) (Figure 3). We observed significant elevated 251 circulating levels of troponin I, IL-1ra, IL-6, IL-17F, TGFα, CCL21, CCL1, CCL8, and CCL17 in patients with CH. We then sought to investigate if specific CH mutations were associated with 252 253 specific cytokines/chemokines. In HCM patients with germline P/LP sarcomeric variants, those with CH due to DNMT3A (N=16) mutations showed higher levels of IL-9 and CXCL12. TET2 CH 254 255 carriers (N=6) showed higher levels of troponin I, IL-5, IL-10, CXCL10, CXCL9, CCL4, VEFG-A, 256 CCL21, CXCL13 and CCL1. Cytokines, chemokines, troponin I and B-type natriuretic peptide

- results among HCM patients with a germline P/LP sarcomeric variant and with or without CH is
- shown in Supplementary Table 9.

260 Discussion

The heterogeneity in HCM patients arises from mutations interacting with genetic and 261 nongenetic factors.²⁴ Our study found a higher CH prevalence in HCM patients, linked to more 262 263 symptoms, ABPR during exercise, fibrosis and MACE. In addition, there were differential levels of circulating cytokines/chemokines and troponin in HCM patients with CH, highlighting a 264 potential causal mechanism between the phenotype and outcomes. This is the first description 265 of an association between CH prevalence, HCM phenotype and clinical outcomes. 266 267 Population studies have shown that CH prevalence ranges between 0-29% and increases with age.¹¹ However, CH prevalence depends on assay sensitivity, VAF cut-off and the selected 268 population of interest.^{11,25,26} In the present study, we found that 22.9% of HCM patients 269 harboured CH mutations. Although most CH mutations were found in those >50 years, 25.9% of 270 the patients <30 years also had CH in our study. Interestingly, somatic mutations in 271 haematopoietic stem cells occurring in the first decades of life are polyclonal and have 272 unknown long-term effects.^{27,28} 273 274 Many studies have focused on the most common gene variants, such as DNMT3A, TET2 and ASXL1^{9,12,22,26,29}, present in 17% of HCM patients with CH mutations. Unsurprisingly, we found 275 that HCM patients with these specific genes showed worse clinical phenotype and outcome, 276 similarly to other patient cohorts.^{9,12,26,29} Experiments have shown that CH mediated by these 277 genes were also associated with LV remodelling and interstitial fibrosis^{14,16,30–32}, with evidence 278

of macrophages migrating to the myocardium and enhancing systemic inflammation.^{15,16}

HCM is characterized by asymmetric LV hypertrophy accompanied by LV outflow tract
obstruction and myocardial fibrosis.¹ While the CH impact on HCM was never explored in
animal models, we observed that MLVWT was not affected by CH, even when restricting to
gene-positive HCM patients. The HCM expression occurring before the acquisition of CH
mutations may explain this lack of association.

Fibrosis was more common in patients with HCM who have a sarcomeric P/LP variant and 285 DNMT3A, TET2 and ASXL1 somatic mutations. These patients also exhibited higher levels of 286 inflammatory cytokines/chemokines, potentially contributing to increased fibrosis. This is an 287 important finding as fibrosis is linked to SCD in patients with HCM.³³ In addition, ABPR at 288 exercise, a prognostic marker in HCM³⁴, was also more frequent among those with CH and HCM 289 290 with sarcomeric germline P/LP variants. This result potentially illustrates that CH could affect 291 the HCM phenotype and promote adverse outcomes. Thus, these observations may reflect a '2-292 hit' sequence of events with the first hit being the germline P/LP sarcomeric mutation followed by the second hit driven by CH. 293

In this study, we showed that, in subsets of HCM patients, the mortality or need for OHT is

increased among CH patients even when adjusting for confounding factors, being in

296 consonance with prior studies.^{9,12,22,26,29,35} In addition, a higher CH associated risk was observed

297 in those with sarcomeric P/LP variants and/or specific CH genes. Our results do not address the

298 specific CH mechanisms involved, but we hypothesize that epigenetic aging and the

299 inflammatory milieu may drive these outcomes.

The increased inflammatory pathways recently shown in HCM^{18,36} associated with higher levels 300 of circulating inflammatory cytokines/chemokines in CH,^{9,15,16} may have a role in driving worse 301 outcomes. In fact, we observed higher circulating levels of several inflammatory cytokines, 302 chemokines, and troponin I among those with CH. However, specific CH mutations may have 303 distinct inflammatory profiles.^{9,22} We observed that DNMT3A-driven CH was associated with IL-304 9 and CXCL12. TET2-driven CH was associated with the higher circulating levels of a different 305 array of cytokines/chemokines including troponin I. Our own previous work has shown that 306 307 TET2-driven CH have been associated with a higher inflammatory milieu and a higher lethality, not seen with DNMT3A.9,16,25,30 308 309 Limitations 310 311 There are several limitations that should be considered. Despite minimal biospecimen-to-312 echocardiogram timing, CH evaluation to MRI time varied (median 2.2 years, range <1 to almost 6 years). As fibrosis can progress among HCM patients⁷, it could have influenced the results. 313 Exclusion of non-MRI patients could introduce a selection bias. The low number of events limits 314 our conclusions especially in those without germline P/LP variants. Further cohorts needed to 315 316 fully evaluate CH's impact on HCM. 317 Conclusions 318 319 The variability in the expression of the HCM phenotype could be explained by an interaction of

320 genetic and epigenetic regulators. This study showed that the CH prevalence among HCM

- 321 patients is higher than expected for a similar age. CH was associated with the presence of
- fibrosis and with poorer outcomes. CH is a new paradigm in HCM, impacting the phenotype and
- 323 prognosis.
- 324

325 **REFERENCES**

- Maron BJ, Desai MY, Nishimura RA, et al. Diagnosis and evaluation of hypertrophic
 cardiomyopathy: JACC state-of-the-art review. *J Am Coll Cardiol*. 2022;79(4):372-389.
 doi:10.1016/j.jacc.2021.12.002
- Authors/Task Force members, Elliott PM, Anastasakis A, et al. 2014 ESC guidelines on
 diagnosis and management of hypertrophic cardiomyopathy: the task force for the
 diagnosis and management of hypertrophic cardiomyopathy of the European Society of
 Cardiology (ESC). *Eur Heart J.* 2014;35(39):2733-2779. doi:10.1093/eurheartj/ehu284
- Maron BJ, Desai MY, Nishimura RA, et al. Management of hypertrophic cardiomyopathy:
 JACC state-of-the-art review. *J Am Coll Cardiol*. 2022;79(4):390-414.
 doi:10.1016/j.jacc.2021.11.021
- 3364.Maron BJ, Haas TS, Goodman JS. Hypertrophic cardiomyopathy: One gene ··· but many337phenotypes. Am J Cardiol. 2014;113(10):1772-1773. doi:10.1016/j.amjcard.2014.02.032
- Rowin EJ, Maron BJ, Maron MS. The hypertrophic cardiomyopathy phenotype viewed through the prism of multimodality imaging: clinical and etiologic implications. *JACC Cardiovasc Imaging*. 2020;13(9):2002-2016. doi:10.1016/j.jcmg.2019.09.020
- Finocchiaro G, Magavern E, Sinagra G, et al. Impact of demographic features, lifestyle,
 and comorbidities on the clinical expression of hypertrophic cardiomyopathy. *J Am Heart Assoc*. 2017;6(12):1-11. doi:10.1161/JAHA.117.007161
- Habib M, Adler A, Fardfini K, et al. Progression of myocardial fibrosis in hypertrophic
 cardiomyopathy: a cardiac magnetic resonance study. *JACC Cardiovasc Imaging*.
 2021;14(5):947-958. doi:10.1016/j.jcmg.2020.09.037
- Maron BABJ, Maron MS, Maron BABJ, Loscalzo J. Moving beyond the sarcomere to
 explain heterogeneity in hypertrophic cardiomyopathy: JACC review topic of the week. J
 Am Coll Cardiol. 2019;73(15):1978-1986. doi:10.1016/j.jacc.2019.01.061
- Scolari FL, Abelson S, Brahmbhatt DH, et al. Clonal haematopoiesis is associated with
 higher mortality in patients with cardiogenic shock. *Eur J Heart Fail*. 2022;24(9):1573 1582. doi:10.1002/ejhf.2588
- Jaiswal S, Natarajan P, Silver AJ, et al. Clonal hematopoiesis and risk of atherosclerotic
 cardiovascular disease. *N Engl J Med*. 2017;377(2):111-121.
 doi:10.1056/NEJMoa1701719
- Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated
 with adverse outcomes. *N Engl J Med*. 2014;371(26):2488-2498.
 doi:10.1056/NEJMoa1408617

359 12. Dorsheimer L, Assmus B, Rasper T, et al. Association of mutations contributing to clonal 360 hematopoiesis with prognosis in chronic ischemic heart failure. JAMA Cardiol. 361 2019;4(1):25-33. doi:10.1001/jamacardio.2018.3965 362 13. Calvillo-Argüelles O, Jaiswal S, Shlush LI, et al. Connections between clonal 363 hematopoiesis, cardiovascular disease, and cancer: A review. JAMA Cardiol. 2019;4(4):380-387. doi:10.1001/JAMACARDIO.2019.0302 364 365 14. Wang Y, Sano S, Yura Y, et al. Tet2-mediated clonal hematopoiesis in nonconditioned 366 mice accelerates age-associated cardiac dysfunction. JCI Insight. 2020;5(6):e135204. doi:10.1172/jci.insight.135204 367 368 15. Sano S, Oshima K, Wang Y, et al. TET2-mediated clonal hematopoiesis accelerates heart failure through a mechanism involving the IL-1β/NLRP3 inflammasome. *J Am Coll Cardiol*. 369 370 2018;71(8):875-886. doi:10.1016/j.jacc.2017.12.037 371 16. Sano S, Oshima K, Wang Y, Katanasaka Y, Sano M, Walsh K. CRISPR-mediated gene editing to assess the roles of TET2 and DNMT3A in clonal hematopoiesis and 372 373 cardiovascular disease. Circ Res. 2018;123(3):335-341. 374 doi:10.1161/CIRCRESAHA.118.313225 375 17. Fuster JJ, MacLauchlan S, Zuriaga MA, et al. Clonal hematopoiesis associated with TET2 376 deficiency accelerates atherosclerosis development in mice. Science. 377 2017;355(6327):842-847. doi:10.1126/science.aag1381 378 18. Coats CJ, Heywood WE, Virasami A, et al. Proteomic analysis of the myocardium in hypertrophic obstructive cardiomyopathy. *Circ Genom Precis Med*. 2018;11(12):e001974. 379 380 doi:10.1161/CIRCGEN.117.001974 381 19. Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy. *Circulation*. 382 2020;142(25):e533-e557. doi:10.1161/CIR.000000000000937 383 384 20. Hoss S, Habib M, Silver J, et al. Genetic testing for diagnosis of hypertrophic 385 cardiomyopathy mimics: yield and clinical significance. Circ Genom Precis Med. 2020;13(4):E002748. doi:10.1161/CIRCGEN.119.002748 386 387 21. de Marvao A, McGurk KA, Zheng SL, et al. Phenotypic expression and outcomes in individuals with rare genetic variants of hypertrophic cardiomyopathy. J Am Coll Cardiol. 388 2021;78(11):1097-1110. doi:10.1016/j.jacc.2021.07.017 389 390 22. Scolari FL, Brahmbhatt DH, Abelson S, et al. Clonal hematopoiesis confers an increased mortality risk in orthotopic heart transplant recipients. Am J Transplant. 2022;22(12). 391 doi:10.1111/ajt.17172 392

Ingles J, Burns C, Bagnall RD, et al. Nonfamilial hypertrophic cardiomyopathy. Circ 393 23. Cardiovasc Genet. 2017;10(2). doi:10.1161/CIRCGENETICS.116.001620 394 395 24. Marian AJ, Braunwald E. Hypertrophic cardiomyopathy: Genetics, pathogenesis, clinical 396 manifestations, diagnosis, and therapy. Circ Res. 2017;121(7):749-770. 397 doi:10.1161/CIRCRESAHA.117.311059 398 25. Young AL, Challen GA, Birmann BM, Druley TE. Clonal haematopoiesis harbouring AMLassociated mutations is ubiquitous in healthy adults. Nat Commun. 2016;7:12484. 399 400 doi:10.1038/ncomms12484 401 26. Assmus B, Cremer S, Kirschbaum K, et al. Clonal haematopoiesis in chronic ischaemic 402 heart failure: prognostic role of clone size for DNMT3A- and TET2-driver gene mutations. 403 Eur Heart J. 2021;42(3):257-265. doi:10.1093/EURHEARTJ/EHAA845 404 27. Watson CJ, Papula AL, Poon GYP, et al. The evolutionary dynamics and fitness landscape of clonal hematopoiesis. Science. 2020;367(6485):1449-1454. 405 406 doi:10.1126/science.aay9333 407 28. Mitchell E, Spencer Chapman M, Williams N, et al. Clonal dynamics of haematopoiesis 408 across the human lifespan. Nature. 2022;606(7913):343-350. doi:10.1038/s41586-022-409 04786-y 410 29. Pascual-Figal DA, Bayes-Genis A, Díez-Díez M, et al. Clonal hematopoiesis and risk of progression of heart failure with reduced left ventricular ejection fraction. J Am Coll 411 412 Cardiol. 2021;77(14):1747-1759. doi:10.1016/j.jacc.2021.02.028 413 30. Sano S, Wang Y, Ogawa H, et al. TP53-mediated therapy-related clonal hematopoiesis 414 contributes to doxorubicin-induced cardiomyopathy by augmenting a neutrophil-415 mediated cytotoxic response. JCI Insight. 2021;6(13). doi:10.1172/jci.insight.146076 416 31. Sano S, Wang Y, Yura Y, et al. JAK2-V617F-Mediated clonal hematopoiesis accelerates pathological remodeling in murine heart failure. JACC Basic Transl Sci. 2019;4(6):684-697. 417 418 doi:10.1016/j.jacbts.2019.05.013 419 32. Min KD, Polizio AH, Kour A, Thel MC, Walsh K. Experimental ASXL1-mediated clonal hematopoiesis promotes inflammation and accelerates heart failure. J Am Heart Assoc. 420 421 2022;11(19). doi:10.1161/JAHA.122.026154 422 33. Bittencourt MI, Cader SA, Araújo DV, et al. Role of myocardial fibrosis in hypertrophic 423 cardiomyopathy: A systematic review and updated meta-analysis of risk markers for sudden death. Arg Bras Cardiol. 2019;112(3):281-289. doi:10.5935/abc.20190045 424 425 34. Sadoul N, Prasad K, Elliott PM, Bannerjee S, Frenneaux MP, McKenna WJ. Prospective prognostic assessment of blood pressure response during exercise in patients with 426

- 427 hypertrophic cardiomyopathy. *Circulation*. 1997;96(9):2987-2991.
 428 doi:10.1161/01.CIR.96.9.2987
- 429 35. Cremer S, Kirschbaum K, Berkowitsch A, et al. Multiple somatic mutations for clonal
 430 hematopoiesis are associated with increased mortality in patients with chronic heart
- 431 failure. *Circ Genom Precis Med*. 2020;13(4):340-342. doi:10.1161/CIRCGEN.120.003003
- 432 36. Shimada YJ, Raita Y, Liang LW, et al. Comprehensive proteomics profiling reveals
- 433 circulating biomarkers of hypertrophic cardiomyopathy. *Circ Heart Fail*.
- 434 2021;14(7):E007849. doi:10.1161/CIRCHEARTFAILURE.120.007849

435

437 **FIGURES LEGENDS**

438 Central figure. Survival in HCM according to somatic CH-related mutations and sarcomeric

439 germline P/LP variants.

- 440 HCM patients with CH and germline sarcomeric gene LP/P variants show the worse prognosis in
- 441 comparison to HCM patients without CH or without germline sarcomeric gene LP/P variants,
- 442 highlighting that the presence of both risk factors warrants concern.
- 443 (CH, clonal haematopoiesis ; G, germline sarcomeric gene P/LP variants; LP, likely pathogenic; P,

444 pathogenic).

445

Figure 1. Somatic mutations related to CH in patients with HCM.

- Panel A shows the number of mutations in the most common affected genes in the cohort..
- Panel B shows the number of mutations per patients in those with clonal haematopoiesis .CH.
- 449 Panel C shows the number of patients with CH according to the decade of the assessment. (CH,
- 450 clonal haematopoiesis ; HCM, hypertrophic cardiomyopathy).

451

452 **Figure 2. Survival in patients with HCM stratified according to CH.**

- 453 Panel A shows the survival according to the presence of CH among HCM patients. Panel B
- 454 shows the survival according to the presence of clonal haematopoiesis in the DNMT3A, TET2,
- and *ASXL1* genes among HCM patients. Panel C shows the survival according to the presence of
- 456 clonal haematopoiesis among HCM patients with germline P/LP sarcomeric variants. Panel D

	457	shows the survival according to the presence of clonal haematopoiesis in the DNMT3A,	TET2,
--	-----	--	-------

- 458 and ASXL1 genes among HCM patients with germline P/LP sarcomeric variants. (CH, clonal
- 459 haematopoiesis; HCM, hypertrophic cardiomyopathy; P/LP, pathogenic/likely pathogenic).

460

461	Figure 3. Troponin I.	cvtokines and chemokines levels amon	g HCM with germline sarcomeric
101	inguic of hopoining		

- 462 **P/LP variant according to CH.** (CH, clonal haematopoiesis; HCM, hypertrophic cardiomyopathy,
- 463 P/LP, pathogenic/likely pathogenic).
- 464 HCM patients with germline sarcomeric genes LP/P variants show upregulated levels of
- 465 Troponin I, cytokines and chemokines.

467	TABLES

Table 1. Overall characteristics of the HCM cohort and between those with or without CH.					
	All	No CH	СН	Р	
	(N=799)	(N=616)	(N=183)		
Age, mean (SD), years	55.7 (14.6)	55.3 (14.5)	57.2 (14.8)	0.126	
Age at diagnosis, mean (SD), years	47.8 (15.8)	47.3 (15.6)	49.6 (16.3)	0.089	
Male sex, No. (%)	547 (68.5)	424 (68.8)	123 (67.2)	0.679	
Body mass index ¹ , mean (SD), kg/m ²	29.0 (6.9)	29.0 (7.1)	29.2 (6.2)	0.647	
Hypertension, No. (%)	315 (39.4)	233 (37.8)	82 (44.8)	0.093	
Diabetes, No. (%)	104 (13.0)	78 (12.6)	26 (14.2)	0.863	
Prior/current smoker, No. (%)	155 (19.3)	119 (19.3)	36 (19.6)	0.637	
Coronary artery disease, No. (%)	73 (9.1)	61 (9.9)	12 (6.5)	0.166	
Atrial fibrillation, No. (%)	143 (17.8)	107 (17.3)	36 (19.6)	0.493	
Genetic testing, No. (%)	712 (89.1)	554 (89.9)	158 (86.3)	0.170	
Germline pathogenic/likely pathogenic	206 (25.8)	169 (30.5)	37 (23.4)	0.083	
sarcomeric variant, No. (%)					
<i>MYH7,</i> No. (%)	53 (25.7)	43 (25.6)	10 (27.0)	0.664	
<i>MYBPC3,</i> No. (%)	127 (61.6)	106 (63.1)	21 (56.8)		
Other, No. (%)	26 (12.6)	20 (11.8)	6 (16.2)		
Family history of HCM, No. (%)	251 (31.4) 194 (31.5) 57 (31.1)		57 (31.1)	0.087	
Family history of SCD, No. (%)	37 (4.6)	26 (4.2)	11 (6.0)	0.048	

Implantable cardioverter defibrillator, No.	111 (13.9)	89 (14.4)	22 (12.0)	0.405			
(%)							
Pacemaker, No. (%)	13 (1.6)	6 (1.0)	7 (3.8)	0.007			
NYHA II-IV, No. (%)	235 (29.4)	182 (29.5)	53 (28.9)	0.803			
Beta-blocker, No. (%)	421 (52.7)	321 (52.1)	100 (54.6)	0.547			
Non-dihydropyridine calcium channel	116 (14.5)	77 (12.5)	39 (21.3)	0.003			
blocker, No. (%)							
Disopyramide, No (%)	67 (8.4)	51 (8.3)	16 (8.7)	0.842			
Diuretic, No (%)	81 (10.1)	59 (9.5)	22 (12.0)	0.303			
Septal reduction therapy, No. (%)	76 (9.5)	53 (8.6)	23 (12.5)	0.130			
Abbreviations: CH, clonal haematopoiesis; HCM, hypertrophic cardiomyopathy; SCD, sudden							
cardiac death							
¹ Body mass index calculated as weigh (kg)/height ² (m)							

Table 2. Clinical phenotype and outcomes according to CH and specific CH-related genes among HCM patients with germline P/LP sarcomeric variants All-CH DNMT3A, TET2, ASXL1 No CH СН No CH СН р р (N=169) (N=37) (N=169) (N=23) Echocardiogram 17.3 (4.6) 17.6 (5.1) 17.4 (4.7) 17.5 (4.9) MLVWT, mean (SD), mm 0.765 0.852 LA diameter, mm 3.9 (1.2) 3.8 (1.1) 0.651 3.9 (1.2) 3.7 (1.4) 0.643 LAVi, ml/m² 38.5 (30.8) 38.5 (30.8) 41.3 (20.7) 0.599 35.6 (20.3) 0.655 LV EF, % 58.2 (15.3) 62.4 (6.2) 0.106 58.2 (15.3) 63.0 (7.3) 0.149 LVOT maximal gradient, mm Hg 17.2 (26.6) 22.5 (40.3) 0.316 17.2 (26.6) 22.6 (43.5) 0.402 SAM, No. (%) 76 (45.0) 21 (56.8) 0.193 76 (45.0) 13 (56.5) 0.297 Moderate-severe MR, No. (%) 7 (4.1) 1 (2.7) 0.681 7 (4.1) 0 0.320

Cardiac MRI

LV mass, g	137.3 (52.9)	143.1 (61.4)	0.601	137.3 (52.9)	142.3 (65.5)	0.703
LV mass index, g/m ²	72.1 (25.5)	74.7 (27.2)	0.622	72.1 (25.5)	73.1 (30.2)	0.876
MLVWT, mm	18.9 (6.4)	19.2 (5.6)	0.814	18.9 (6.4)	19.0 (5.8)	0.989
LV EF, %	60.8 (8.3)	62.1 (6.2)	0.390	60.8 (8.3)	61.1 (5.8)	0.884
LGE, No (%)	134 (79.3)	27 (73.0)	0.400	134 (79.3)	17 (73.9)	0.555
LGE >15%, No (%)	26 (17.7)	11 (33.3)	0.044	26 (17.7)	7 (35.0)	0.068
LV mass % of LGE ¹ , %	12.2 (7.7-17.6)	15.6 (10.4-	0.068	12.2 (7.7-17.8)	21.2 (13.7-	0.017
		24.6)			41.8)	
Apical Aneurysm, No (%)	1 (0.6)	1 (2.7)	0.145	1 (0.6)	0	0.711
Syncope, No (%)	6 (3.6)	3 (8.1)	0.219	6 (3.6)	2 (8.7)	0.247
ABPR at exercise, No. (%) (85/15)	25 (29.8)	10 (62.5)	0.012	25 (29.8)	8 (66.7)	0.012
NVST, No. (%) (145/21)	52 (37.7)	11 (39.3)	0.873	52 (37.7)	7 (41.2)	0.779
Outcomes						
Stroke, No. (%)	2 (1.2)	2 (5.4)	0.092	2 (1.2)	1 (4.3)	0.251
Appropriate ICD shock, No. (%)	2 (1.2)	0	0.506	2 (1.1)	0	0.614

Cardiac arrest, No. (%) 0 0 n/a 0 n/a								
Death or orthotopic heart transplant, No. 2 (1.2) 3 (8.1) 0.013 2 (1.2) 3 (13.0) <0.0001								
(%)								
MACE, No. (%) 5 (3.0) 5 (13.5) 0.008 5 (3.0) 4 (17.4) .003								
¹ Quantified LGE>5%.								
ABPR, abnormal blood pressure response; EF, ejection fraction; LA, left atrium diameter; LAVi, left atrium volume index; ICD, implantable								
cardioverter defibrillator; LGE, late gadolinium enhancement; LV, left ventricle; LVOT, left ventricular outflow tract; MACE, major								
cardiovascular events; MLVWT, maximal left ventricular wall thickness; MR, mitral regurgitation; MRI, magnetic resonance imaging; NSVT,								
non-sustained ventricular tachycardia; P/LP, pathogenic/likely pathogenic; SAM, systolic anterior motion;								











ŀ



ile depicts and the depicts of the d



